JANX News and Press, Janux Therapeutics Inc. From 08/31/22

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today annou...

Janux Therapeutics press release ( NASDAQ: JANX ): Q2 GAAP EPS of -$0.41. Collaboration Revenue of $2.37M. The company had $354.3 million in cash and cash equivalents and short-term investments at end of second quarter 2022 For further details see: Janux Ther...

-IND application cleared for lead product candidate JANX007 (PSMA-TRACTr)- -Phase 1 clinical trial evaluating JANX007 for metastatic castration-resistant prostate cancer remains on-track to initiate in 2H 2022- -IND application for EGFR-TRACTr (JANX008) remains on-trac...